Silmitasertib

CX-4945 · Senhwa Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Silmitasertib, covering 2025-01-27 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors [Phase 1, Phase 2]